- Conditions
- Plasmodium Falciparum Malaria
- Interventions
- Aluminum Phosphate, Placebo, EBA-175 RII-NG Malaria Vaccine
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Castrate-Resistant Prostate Cancer, Hormone Refractory Prostate Cancer
- Interventions
- custirsen sodium, isotonic, 0.9% sodium chloride, docetaxel, cabazitaxel, prednisone
- Drug
- Lead sponsor
- Achieve Life Sciences
- Industry
- Eligibility
- 18 Years to 99 Years · Male only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 20
- States / cities
- La Verne, California • Fort Lauderdale, Florida • Tampa, Florida + 17 more
- Conditions
- Squamous Neck Carcinoma of the Head and Neck Cancer (SCCHN)
- Interventions
- Tirapazamine, Cisplatin, 5-fluorouracil, Radiotherapy (RT)
- Drug · Radiation
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 17 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2005
- U.S. locations
- 2
- States / cities
- Palo Alto, California • Stanford, California
- Conditions
- Advanced Carcinoma, Non-small Cell Lung Cancer
- Interventions
- Aflibercept, Pemetrexed, Cisplatin
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 14
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Stanford, California + 11 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- NKTR-214, Pembrolizumab, Cisplatin, Carboplatin, Nab paclitaxel, Paclitaxel, Pemetrexed, Atezolizumab
- Drug
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 23
- States / cities
- Fayetteville, Arkansas • San Francisco, California • Aurora, Colorado + 19 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Arm A: Pemetrexed Cisplatin, Arm B Pemetrexed, Cisplatin and MK-0646
- Drug
- Lead sponsor
- University of Kansas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 4
- States / cities
- Hutchinson, Kansas • Kansas City, Kansas • Topeka, Kansas + 1 more
- Conditions
- Head and Neck Cancer
- Interventions
- Cisplatin, Elective Nodal Irradiation (ENI)
- Drug · Radiation
- Lead sponsor
- Coastal Carolina Radiation Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 5
- States / cities
- Morehead City, North Carolina • New Bern, North Carolina • Supply, North Carolina + 1 more
- Conditions
- Type1diabetes, Hypoglycemia, Hypoglycemia Unawareness, Islet Cell Transplantation
- Interventions
- Phentolamine, Propranolol, Placebo
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Advanced Cancers, Sarcoma
- Interventions
- Hyperthermic Peritoneal Perfusion (HIPEC), Cisplatin
- Procedure · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel, Placebo in combination with cisplatin and docetaxel or paclitaxel
- Drug
- Lead sponsor
- BioNumerik Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Columbia, Missouri • Philadelphia, Pennsylvania + 1 more
- Conditions
- Adult T-cell Leukemia-Lymphoma
- Interventions
- KW-0761, Pralatrexate, gemcitabine plus oxaliplatin, DHAP
- Biological · Drug
- Lead sponsor
- Kyowa Kirin, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Miami, Florida • Chicago, Illinois + 5 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Albiglutide 50 mg, Placebo, CCK (Kinevac)
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Vaso-occlusive Crisis, Sickle Cell Disease
- Interventions
- Saline, MST-188
- Drug
- Lead sponsor
- Mast Therapeutics, Inc.
- Industry
- Eligibility
- 4 Years to 65 Years
- Enrollment
- 388 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2013
- U.S. locations
- 50
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Oakland, California + 43 more
- Conditions
- Multiple Myeloma
- Interventions
- Velcade, Melphalan, Thalidomide, Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide
- Drug
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2028
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Metastatic Non-small Cell Lung Cancer
- Interventions
- Dato-DXd, Osimertinib, Pemetrexed, Carboplatin, Cisplatin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 744 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 34
- States / cities
- Fayetteville, Arkansas • Duarte, California • Fountain Valley, California + 29 more
- Conditions
- Healthy
- Interventions
- tigecycline, moxifloxacin, 100 mL 0.9% Sodium Chloride intravenous, placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Septic Shock
- Interventions
- hydrocortisone, Normal Saline
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Anemia, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Neutropenia
- Interventions
- darbepoetin alfa, pegfilgrastim, cisplatin, docetaxel, BNP7787
- Biological · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 64
- States / cities
- Mountain View, California • Lewes, Delaware • Newark, Delaware + 42 more
- Conditions
- Thyroid Eye Disease
- Interventions
- Teprotumumab, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 7
- States / cities
- Beverly Hills, California • Los Angeles, California • Palo Alto, California + 4 more
- Conditions
- Transitional Cell Carcinoma of Bladder, Urethra Cancer, Ureter Cancer, Malignant Tumor of Renal Pelvis
- Interventions
- Cisplatin, Gemcitabine, ALT-801
- Drug · Biological
- Lead sponsor
- Altor BioScience
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 16
- States / cities
- Tucson, Arizona • Orlando, Florida • Stuart, Florida + 13 more
- Conditions
- Small Cell Lung Cancer
- Interventions
- Cisplatin
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- Not listed
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Dupuytren's Contracture
- Interventions
- XIAFLEX / XIAPEX
- Biological
- Lead sponsor
- Endo USA Inc., a Keenova Therapeutics Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 715 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Encinitas, California + 22 more
- Conditions
- Pancreatic Neoplasms
- Interventions
- Heckel Infrared Radiant Heat Device, cisplatin, gemcitabine, interferon-alpha, thermochemotherapy
- Device · Other
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Metabolic Syndrome X
- Interventions
- NOS Inhibition, ET-1 Inhibition, NOS Inhibition Placebo, 3 Tesla MRI, Intravenous Catheter, Oral Glucose Tolerance Test, ET-1 Inhibition Placebo
- Drug · Device · Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin